Molecular staging of pelvic surgical margins after radical prostatectomy: Comparison of RT-PCR for prostate-specific antigen and telomerase activity

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 545-549

  Straub, Bernd ^a   Muller, Markus ^a   Krause, Hans ^a   Goessl, Carsten ^a   Schrader, Mark ^a   Heicappell, Rudiger ^a   Miller, Kurt ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Polymerase chain reaction; Prostate cancer; Staging; Telomerase activity

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TELOMERASE;

AGED; ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE;

AGED; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TELOMERE;

EID: 0036585005     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.545     Document Type: Article

References (34)

1. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H and Bartsch G: Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 36: 1322-1335, 2000.
2. Bai XZ, Masters JR, O'Donoghue N, Kirby R, Pan LX, Young M, Stafford M and Parkinson MC: Prognostic markers in clinically localised prostate cancer. Int J Oncol 14: 785-791, 1999.
3. Geary ES and Stamey TA: Pathological characteristics and prognosis of non-palpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng/ml. J Urol 156: 1056-1058, 1996. (Pubitemid 26269828)
4. Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW and Sesterhenn IA: Prostate-specific antigen-detected prostate cancer (stage Tic): an analysis of whole-mount prostatectomy specimens. Prostate 32: 59-64, 1997. (Pubitemid 27274361)
5. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP Jr and Pontes JE: Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate 39: 60-66, 1999. (Pubitemid 29143111)
6. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP and Wein A: Optimizing patients selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys 45: 1227-1233, 1999.
7. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H and Bostwick DG: Preoperative predicition of surgical margin status in patients with prostate cancer treated bv radical prostatectomy. J Clin Oncol 18: 2862-2868, 2000. (Pubitemid 30620074)
8. Mettlin CJ, Murphy GP, Sylvester J, McKee RF, Morrow M and Winchester DP: Results of hospital cancer registry by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy. Cancer 80: 1875-1881, 1997. (Pubitemid 27475952)
9. Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP and Bostwick DG: Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 86: 1775-1782, 1999. (Pubitemid 29513047)
10. Obek C, Sadek S, Lai S, Civantos F, Rubinowicz D and Soloway MS: Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology 54: 682-688, 1999. (Pubitemid 29449430)
11. Fesseha T, Sakr W, Grignon D, Banerjee M, Wood DP Jr and Pontes JE: Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol 158: 2176-2179, 1997. (Pubitemid 27481352)
12. Grossfeld GD, Tigrani VS, Nudell D, Roach M III, Weinberg VK, Presti JC Jr, Small EJ and Carroll PR: Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 164:93-99, 2000.
13. Henke RP, Hammerer P, Graefen M, Erbersdobler A, Neumann M, Berger J and Huland H: Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer 83: 977-988, 1998. (Pubitemid 28401933)
14. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sozen S and Gill H: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 160: 2412-2417, 1998. (Pubitemid 29483052)
15. Boccon-Gibod L, Ravery V, Vordos D, Toublanc M, Delmas V and Boccon-Gibod L: Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. J Urol 160: 1383-1385, 1998. (Pubitemid 29480521)
16. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M and Scardino PT: Clinical and pathological significance of the level and extent of capsular invasion in clinical stage Tl-2 prostate cancer. Hum Pathol 29: 856-862, 1998. (Pubitemid 28375994)
17. Vassilikos EJ, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL and Diamandis EP: Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin Biochem 33: 115-123, 2000. (Pubitemid 30212819)
18. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ and Zincke H: Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 163: 1178-1182, 2000. (Pubitemid 30169386)
19. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Henning JM, Stier DM and Carroll PR: Impact of positive surgical margins on prostate cancer recurrence and the use of secondary treatment: data from the CaPSURE database. J Urol 163: 1171-1177,2000. (Pubitemid 30169385)
20. Jhaveri FM and Klein EA: How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 17: 130-134, 1999. (Pubitemid 29380639)
21. Wieder JA and Soloway MS: Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 160: 299-315, 1998. (Pubitemid 29476668)
22. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gillenwater JY and Kelly MD: Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 39: 681-686, 1997. (Pubitemid 27441437)
23. Okegawa T, Noda H, Kato M, Miyata A, Nutahara K and Higashihara E: Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 44: 210-218, 2000. (Pubitemid 30484504)
24. Okegawa T, Yoshioka J, Morita R, Nutahara K, Tsukada Y and Higashihara E: Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer. Int J Urol 5: 349-356, 1998. (Pubitemid 28398661)
25. De la Taille A, Olsson CA and Katz AE: Molecular staging of prostate cancer: dream or reality? Oncology 13: 187-194, 1999.
26. Theodorescu D, Frierson HF Jr and Sikes RA: Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol 161: 1442-1448, 1999. (Pubitemid 29420792)
27. Straub B, Muller M, Krause H, Goessl C, Schrader M, Heicappell R and Miller K: RT-PCR for prostate-specific antigen in the molecular staging of pelvic surgical margins after radical prostatectomy. Urology 57: 1006-1011, 2001. (Pubitemid 32405334)
28. Heung YM, Walsh K, Sriprasad S, Mulvin D and Sherwood RA: The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int 85: 65-69, 2000. (Pubitemid 30072451)
29. Kyo S, Takakura M and Inoue M: Telomerase activity in cancer as a diagnostic and therapeutic target. Histol Histopathol 15: 813-824, 2000. (Pubitemid 30488564)
30. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW and Coffey DS: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56: 218-222, 1996. (Pubitemid 26011466)
31. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M and Kubota Y: Telomerase activity in primary prostate cancer. J Urol 157: 1161-1165, 1997. (Pubitemid 27066336)
32. Zhang W, Kapusta LR, Slingerland JM and Klotz LH: Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 58: 619-621, 1998. (Pubitemid 28099467)
33. Straub B, Muller M, Krause H, Goessl C, Schrader M, Heicappell R and Miller K: Molecular staging of surgical margins after radical prostatectomy by detection of telomerase activity. Prostate 49: 140-144, 2001. (Pubitemid 32937810)
34. Kim NW, Piatyszek MA and Prowse KR: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.